Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Accumulated Depreciation (2020 - 2025)

Historic Accumulated Depreciation for SAB Biotherapeutics (SABS) over the last 6 years, with Q3 2025 value amounting to $16.8 million.

  • SAB Biotherapeutics' Accumulated Depreciation rose 2145.64% to $16.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.8 million, marking a year-over-year increase of 2145.64%. This contributed to the annual value of $14.6 million for FY2024, which is 4703.52% up from last year.
  • According to the latest figures from Q3 2025, SAB Biotherapeutics' Accumulated Depreciation is $16.8 million, which was up 2145.64% from $16.1 million recorded in Q2 2025.
  • Over the past 5 years, SAB Biotherapeutics' Accumulated Depreciation peaked at $16.8 million during Q3 2025, and registered a low of $3.2 million during Q4 2021.
  • Moreover, its 5-year median value for Accumulated Depreciation was $10.9 million (2023), whereas its average is $10.2 million.
  • As far as peak fluctuations go, SAB Biotherapeutics' Accumulated Depreciation skyrocketed by 9498.42% in 2022, and later skyrocketed by 2145.64% in 2025.
  • Over the past 5 years, SAB Biotherapeutics' Accumulated Depreciation (Quarter) stood at $3.2 million in 2021, then skyrocketed by 94.98% to $6.3 million in 2022, then soared by 57.87% to $9.9 million in 2023, then surged by 47.04% to $14.6 million in 2024, then increased by 15.42% to $16.8 million in 2025.
  • Its last three reported values are $16.8 million in Q3 2025, $16.1 million for Q2 2025, and $15.3 million during Q1 2025.